DTx Pharma was named by the San Diego Venture Group as one of their 30 Cool Companies of 2018
Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, was named by the San Diego Venture Group (SDVG) as one of their 30 Cool Companies of 2018. According to their website, the SDVG considers cool companies to be among the fastest growing and most exciting start-ups in Southern California. DTx Pharma was featured, along with the other 29 Cool Companies, in the San Diego Business Journal (SDBJ Article Link).
Founders of Cool Companies have the opportunity to interact with approximately 100 venture capitalists at a private event in late June. They also get to showcase their company at the Venture Summit in San Diego in August 2018. “It is an honor to be selected as a San Diego cool company,” said Arthur Suckow, CEO/CSO of DTx Pharma. “We really appreciate the efforts of SDVG to try to attract venture capital to start-up companies in the region and look forward to the opportunity to showcase our rapid progress to institutional investors.”
DTx Pharma to Attend 2018 BIO International Convention
San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2018 BIO International Partnering Convention in Boston, MA from June 4-7, 2018.
“The single biggest obstacle limiting the expansion of oligonucleotide therapeutics as a class is delivery,” said Arthur Suckow, Ph.D, CEO/CSO of DTx. “DTx Pharma has developed proprietary technology that has achieved a major breakthrough, and that has, and will continue to break open open new therapeutic areas for this class of medicines. We look forward to meeting with potential partners as we seek to move candidates into early clinical development.
Contact Us Here
DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, is pleased to announce that Jeff Friedman, MD/PhD has been appointed Chief Operating Officer, effective immediately
“Jeff is a valuable addition to the DTx Pharma team. He has served as both a scientific and business advisor since the inception of DTx Pharma and in this role has been instrumental in helping the founding team take an idea through to in vivo proof of concept,” said Arthur Suckow, CEO/CSO and co-founder of DTx Pharma. “His scientific, medical and investing experience will help DTx to identify and successfully engage with high quality partners, investors and advisors as we identify and advance clinical candidates,” said John Grundy, co-founder of DTx Pharma and Vice President of Nonclinical Development & Clinical Pharmacology at Arena Pharmaceuticals. “We are confident that Jeff will have an immediate impact on the execution of our business strategy as we continue to break open new therapeutic areas for oligonucleotide therapeutics,” said Adam Pavlicek, co-founder of DTx Pharma and, founder and CEO of Monoceros Biosystems.
“It is with great excitement that I’m crossing over from an investor/advisor into an operating role for DTx Pharma. This is a passionate and talented team with deep expertise in the oligo therapeutic space. They have gone from an idea to a functional technology more quickly than any other company I’ve been associated with—less than 4 months to proof of concept in both cell culture and in vivo! We have an opportunity to efficiently use capital to build value very quickly—and I’m excited to help my colleagues at DTx as we present this growing value proposition to investors and introduce our technology to potential partners,” said Jeff Friedman, new COO of DTx Pharma.
About Jeff Friedman
Jeff Friedman received his MD and PhD from Stanford University. He trained in Pediatrics and Hematology/Oncology at Boston Children’s Hospital and Dana Farber Cancer Institute, and came to San Diego as an assistant professor at the Scripps Research Institute. He serves in a number of board and advisory roles including for Tech Coast Angels San Diego, where he is a board member and Chair of the life science committee; for CurePSP (a foundation serving patients with Progressive Supranuclear Palsy) where he is a board member and Chair of the Research Committee; for the PSP Genetics Consortium, where he is Managing Director of an international effort sequencing 2,000 whole genomes from autopsy verified PSP cases in a search for risk alleles; for Celsense Inc (a company developing viable dyes for cell tracking in vivo using MRI) where he serves as a board member. As the managing partner of FriedmanBioventure, he oversees a portfolio of more than 45 early stage companies, primarily in the biomedical space.
DTx Pharma accepted into CONNECT Springboard Accelerator Program
DTx Pharma, a RNA-based therapeutics company, announced that it has been accepted into the prestigious CONNECT mentoring program. CONNECT is a program whose graduates have gone onto raise over $1.5 billion dollars in capital and whose companies have created over 4000 jobs. DTx entered expects to graduate in Q2, 2017. Further details on the CONNECT Springboard Accelerator Program are available at http://connect.catalyst-inc.org/springboard-accelerator.
DTx Pharma mentioned by JNJ executive as one of the world’s 20 hottest startups following JLABs portfolio showcase
DTx Pharma, a RNA-based therapeutics company, announced that it was one of 3 companies chosen from the JLABs San Diego site to present a 3-minute pitch to a global audience of investors, executives, physicians, strategic investors and government partners located in New York, San Francisco, Boston, Toronto, Houston and San Diego. Following the presentation, DTx was featured in a note and photograph by Arjun Desai, Vice President of Innovation at Johnson & Johnson, “as one of the 20 hottest startups in the world”.
DTx Pharma adds Jeff Friedman, MD, PhD, Neil Gibson, PhD, and Timothy Scott, JD to Scientific Advisory Board
DTx Pharma, a RNA-based therapeutics company, announced that Jeff Friedman, Neil Gibson and Timothy Scott joined the scientific advisory board in Q3, 2017 Dr. Friedmans the chair of the life sciences arm of the Tech Coast Angels, the managing partner of Friedman Bioventures and serves as Director and Chair of the research committee of CurePSP. Dr. Gibson is currently the chief scientific officer, biologics at COI pharmaceuticals. Previously, he served as the chief scientific officer for Regulus Therapeutics, chief scientific officer and oncology therapeutic area head at Pfizer as well as senior Vice President at BioAtla. Mr. Scott is currently the chief executive officer of TEGA therapeutics and serves on the board of Avelas and Orphan Pharmaceuticals. Last year, he sold a company he founded, Pharmatek, to Catalent Therapeutics.